BenchTop Validation of UNICORN Leaflet Modification Technique in Redo-Transcatheter Aortic Valve Replacement.
SC, L., HAC, C., KE, C., DT, C., YT, L., P, L., SY, S., CW, L., J, S., & FC, T. (2026). BenchTop Validation of UNICORN Leaflet Modification Technique in Redo-Transcatheter Aortic Valve Replacement.. JACC. Cardiovascular interventions. https://doi.org/10.1016/j.jcin.2026.04.034
SC L, HAC C, KE C, DT C, YT L, P L, et al. BenchTop Validation of UNICORN Leaflet Modification Technique in Redo-Transcatheter Aortic Valve Replacement.. JACC. Cardiovascular interventions. 2026; doi: 10.1016/j.jcin.2026.04.034
SC L, HAC C, KE C, et al. BenchTop Validation of UNICORN Leaflet Modification Technique in Redo-Transcatheter Aortic Valve Replacement.[J]. JACC. Cardiovascular interventions. 2026. DOI: 10.1016/j.jcin.2026.04.034.
@article{sc2026,
author = {Lam SC and Chiu HAC and Chan KE and Chan DT and Lee YT and Lin P and Sze SY and Lee CW and Shek J and Tam FC},
title = {BenchTop Validation of UNICORN Leaflet Modification Technique in Redo-Transcatheter Aortic Valve Replacement.},
journal = {JACC. Cardiovascular interventions},
year = {2026},
doi = {10.1016/j.jcin.2026.04.034},
note = {PMID: 42331409},
}
TY - JOUR AU - Lam SC AU - Chiu HAC AU - Chan KE AU - Chan DT AU - Lee YT AU - Lin P AU - Sze SY AU - Lee CW AU - Shek J AU - Tam FC TI - BenchTop Validation of UNICORN Leaflet Modification Technique in Redo-Transcatheter Aortic Valve Replacement. T2 - JACC. Cardiovascular interventions PY - 2026 DO - 10.1016/j.jcin.2026.04.034 AN - PMID:42331409 ER -
BACKGROUND: Coronary obstruction is a critical risk in valve-in-valve transcatheter aortic valve replacement (TAVR). The UNICORN (undermining iatrogenic coronary obstruction with radiofrequency needle) technique mitigates this risk via intraleaflet valve deployment. However, comprehensive bench testing data regarding this technique is lacking in the literature. OBJECTIVES: The aims of this study were to evaluate leaflet behavior after intraleaflet balloon dilatation across different transcatheter heart valve (THV) platforms, simulate the crossing of a second THV across de novo fenestrations, and understand leaflet behavior during and after deployment. METHODS: In vitro bench testing used 4 index THV platforms: SAPIEN 3, Evolut, Navitor, and ACURATE neo2. Following leaflet traversal, target leaflets underwent sequential balloon dilatation (8-14 mm). We assessed the maximum balloon size tolerated without laceration, the minimum size required for a second balloon-expandable THV (SAPIEN 3 Ultra RESILIA) to cross the fenestration, deployment feasibility, and postdeployment valve geometry. RESULTS: Most index THV leaflets tolerated balloon dilatation up to 12 to 14 mm without laceration. A minimum fenestration size of 12 to 14 mm facilitated most of the second THV crossing. Postdeployment models confirmed coronary clearance on the treated side. Successful intraleaflet THV deployment was achieved with the SAPIEN 3, Evolut, and ACURATE neo2. Conversely, intraleaflet deployment in the Navitor (and Portico) platform was unsuccessful; the leaflet remained intact following expansion, resulting in frame distortion and inner-valve tilting possibly due to stiff leaflet and compliant frame. CONCLUSIONS: This bench study defines optimal balloon sizing for UNICORN across common THV platforms and confirms coronary clearance. It was determined that one index valve resisted intraleaflet deployment. Further clinical validation is required before widespread adoption.